Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An organosulfur compound used as a solvent in industry and in medicine as an excipient in order to increase the percutaneous absorption of other substances (Marren 2011, Turnbull 1969, Baker 1968) and as topical, cutaneous and intravesical antalgic anti-inflammatory agents (Rawls 2017).
In industrial management there are no established TLVs. It causes irritation of the eyes, skin and mucous membranes (PanReac 2017, INSHT 2010).
It is eliminated via the skin and breathing, producing a garlic-like odour.
Since the last update date we have not found published data on its excretion in breastmilk.
Following dermal or bladder application, absorption through the skin or mucous membranes is high and rapid so its excretion in milk is likely.
With regard to occupational risks for breastfeeding mothers (INSHT 2017 and 2008, EC Regulation 2008), the risk phrases (formerly R phrases, currently H-phrases for Hazard) or of precautionary (P-phrases) that should appear on a product’s safety data sheet are only two:
- H362 (ant. R64): "It may harm children who are breastfed"
- P263: "Avoid contact during pregnancy and breastfeeding”.
Another three phrases that should be considered during breastfeeding are related to the carcinogenic, mutagenic or cumulative effects of a product:
- H351 (ant. R40): "Possible carcinogenic effects"
- H371 (ant. R68): "Possibility of irreversible effects"
- H373 (ant. R33) : "Danger of cumulative effects”
Based on the absence of these phrases in the Dimethyl sulfoxide Safety Data Sheet (INSHT 2010, Acofarma 2010), it would not be necessary to remove the breastfeeding mother from her workplace, it would be enough for the company to meet the legal requirements regarding the maximum levels of environmental exposure and for the employee to follow recommended rules of caution (gloves, hand and face washing, change of clothes, etc.) (PanReac 2017, INSHT 2010, Acofarma 2010).